Mechanism of Action of BiTE Immunotherapy
Joshua K. Sabari, MD, discusses how tarlatamab, a BiTE, demonstrates a unique mechanism of action by targeting DLL3, which is aberrantly expressed in 85% to 94% of SCLC cells, thereby directing T cells to these cancer cells independently of MHC class I and promoting T-cell–mediated tumor lysis and regression.
Video content above is prompted by the following:
Please discuss the unique mechanism of action of tarlatamab, a BiTE, and its treatment potential as subsequent therapy for SCLC that has progressed after platinum-based chemotherapy.
Recent Videos
Related Content
